June Raine, MHRA chief executive (Frank Augstein/AP Images, Pool)
Amicus scores another approval in the UK for Pompe disease therapy, expects FDA OK in Q3
The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted a marketing authorization for Amicus Therapeutics’ combo therapy for late-onset Pompe disease …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
